Dashboard
1
Poor Management Efficiency with a low ROCE of 3.56%
- The company has been able to generate a Return on Capital Employed (avg) of 3.56% signifying low profitability per unit of total capital (equity and debt)
2
Poor long term growth as Net Sales has grown by an annual rate of 10.34% and Operating profit at -18.44% over the last 5 years
3
With ROE of 2.95%, it has a expensive valuation with a 2.33 Price to Book Value
Stock DNA
Pharmaceuticals & Biotechnology
CNY 2,400 Million (Small Cap)
79.00
NA
1.24%
0.15
2.95%
2.33
Revenue and Profits:
Net Sales:
311 Million
(Quarterly Results - Jun 2025)
Net Profit:
15 Million
Total Returns (Price + Dividend) 
TimePeriod
Price Return
Dividend Return
Total Return
3 Months
12.43%
0%
12.43%
6 Months
15.38%
0%
15.38%
1 Year
0.18%
0%
0.18%
2 Years
-1.55%
0%
-1.55%
3 Years
-13.37%
0%
-13.37%
4 Years
-27.74%
0%
-27.74%
5 Years
-51.16%
0%
-51.16%
Zhejiang Canaan Technology Ltd. for the last several years.
Risk Adjusted Returns v/s 
News
No Recent News for the Company
Announcements 
No announcement available
Corporate Actions 
No corporate action available
Quality key factors 
Factor
Value
Sales Growth (5y)
10.34%
EBIT Growth (5y)
-18.44%
EBIT to Interest (avg)
1.65
Debt to EBITDA (avg)
0.80
Net Debt to Equity (avg)
0.18
Sales to Capital Employed (avg)
0.78
Tax Ratio
11.27%
Dividend Payout Ratio
82.30%
Pledged Shares
0
Institutional Holding
0
ROCE (avg)
3.56%
ROE (avg)
3.60%
Valuation key factors
Factor
Value
P/E Ratio
79
Industry P/E
Price to Book Value
2.33
EV to EBIT
88.26
EV to EBITDA
28.36
EV to Capital Employed
2.15
EV to Sales
1.86
PEG Ratio
0.41
Dividend Yield
1.24%
ROCE (Latest)
2.44%
ROE (Latest)
2.95%
Technicals key factors
Indicator
Weekly
Monthly
MACD
Bullish
Bullish
RSI
No Signal
No Signal
Bollinger Bands
Mildly Bullish
Mildly Bullish
Moving Averages
Bullish (Daily)
KST
Mildly Bearish
Bullish
Dow Theory
Mildly Bullish
Mildly Bearish
OBV
Bullish
Bullish
Shareholding Snapshot
No data for shareholding present.
Shareholding Compare (%holding) 
No data for shareholding present.
Quarterly Results Snapshot (Consolidated) - Jun'25 - YoY
Jun'25
Jun'24
Change(%)
Net Sales
310.80
331.50
-6.24%
Operating Profit (PBDIT) excl Other Income
30.00
35.30
-15.01%
Interest
4.10
3.90
5.13%
Exceptional Items
-0.30
0.00
Consolidate Net Profit
14.60
23.10
-36.80%
Operating Profit Margin (Excl OI)
40.90%
65.20%
-2.43%
USD in Million.
Net Sales
YoY Growth in quarter ended Jun 2025 is -6.24% vs 19.98% in Jun 2024
Consolidated Net Profit
YoY Growth in quarter ended Jun 2025 is -36.80% vs 92.50% in Jun 2024
Annual Results Snapshot (Consolidated) - Dec'24
Dec'24
Dec'23
Change(%)
Net Sales
1,371.40
1,040.10
31.85%
Operating Profit (PBDIT) excl Other Income
96.30
12.00
702.50%
Interest
15.80
7.30
116.44%
Exceptional Items
1.60
0.10
1,500.00%
Consolidate Net Profit
30.40
-27.90
208.96%
Operating Profit Margin (Excl OI)
30.70%
-34.20%
6.49%
USD in Million.
Net Sales
YoY Growth in year ended Dec 2024 is 31.85% vs -5.08% in Dec 2023
Consolidated Net Profit
YoY Growth in year ended Dec 2024 is 208.96% vs 66.55% in Dec 2023
About Zhejiang Canaan Technology Ltd. 
Zhejiang Canaan Technology Ltd.
Pharmaceuticals & Biotechnology
No Details Available.
Company Coordinates 
No Company Details Available






